Arcturus Therapeutics (ARCT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ARCT Stock Forecast

Arcturus Therapeutics stock forecast is as follows: an average price target of $9.58 (represents a -38.11% downside from ARCT’s last price of $15.48) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

ARCT Price Target

The average price target for Arcturus Therapeutics (ARCT) is $9.58 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $10.58 to $8.58. This represents a potential -38.11% downside from ARCT's last price of $15.48.

ARCT Analyst Ratings

Buy

According to 7 Wall Street analysts, Arcturus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ARCT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).

Arcturus Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 11, 2024	Whitney Ijem	Canaccord Genuity	$10.58	$3.02	250.33%	-31.65%
Aug 06, 2024	Whitney Ijem	Canaccord Genuity	$10.30	$3.20	221.88%	-33.46%
Jul 02, 2024	Ed Arce	H.C. Wainwright	$8.58	$3.38	153.85%	-44.57%
May 31, 2024	Yasmeen Rahimi	Piper Sandler	$20.02	$5.64	254.96%	29.33%
May 10, 2024	Whitney Ijem	Canaccord Genuity	$12.30	$3.83	221.15%	-20.54%
Mar 19, 2024	Yale Jen	Laidlaw	$11.30	$4.83	133.95%	-27.00%
Nov 02, 2022	Gena Wang	Barclays	$25.00	$21.69	15.26%	61.50%
May 11, 2022		Goldman Sachs	$14.00	$13.55	3.28%	-9.56%
Nov 09, 2021	Madhu Kumar	Goldman Sachs	$30.00	$36.23	-17.20%	93.80%

The latest Arcturus Therapeutics stock forecast, released on Nov 11, 2024 by Whitney Ijem from Canaccord Genuity, set a price target of $10.58, which represents a 250.33% increase from the stock price at the time of the forecast ($3.02), and a -31.65% decrease from ARCT last price ($15.48).

Arcturus Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	6
Avg Price Target	-	$10.58	$12.18
Last Closing Price	$15.48	$15.48	$15.48
Upside/Downside	-100.00%	-31.65%	-21.32%

In the current month, the average price target of Arcturus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcturus Therapeutics's last price of $15.48. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	Leerink Partners	Buy	Buy	Hold
Oct 01, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Sep 17, 2024	Canaccord Genuity	Buy	Buy	Hold
Aug 07, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 02, 2024	Piper Sandler	Overweight	Overweight	Hold
Jul 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 07, 2024	William Blair	Outperform	Outperform	Hold
May 31, 2024	Piper Sandler	Overweight	Overweight	Hold
May 29, 2024	Citigroup	Buy	Buy	Hold
Mar 11, 2024	Wells Fargo	Buy	Buy	Hold
Mar 11, 2024	Citigroup	Underperform	Underperform	Hold
Jul 24, 2023	William Blair		Outperform	Initialise
Nov 03, 2022	Citigroup		Buy	Upgrade
May 11, 2022	Goldman Sachs	Sell	Sell	Hold

Arcturus Therapeutics's last stock rating was published by Leerink Partners on Oct 01, 2024. The company gave ARCT a "Buy" rating, the same as its previous rate.

Arcturus Therapeutics Financial Forecast

Arcturus Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$33.99M	-	$10.52M	$79.73M	$160.05M	$13.37M	$27.09M	$5.24M	$5.79M	$2.44M	$2.00M	$2.13M	$2.24M	$2.33M	$2.32M	$2.65M	$2.97M	$3.32M
Avg Forecast	$230.30M	$190.91M	$123.96M	$120.31M	$74.24M	$65.36M	$75.05M	$53.00M	$45.92M	$36.59M	$22.23M	$17.67M	$37.86M	$15.85M	$49.33M	$37.94M	$9.75M	$4.57M	$3.14M	$7.08M	$14.75M	$21.76M	$2.53M	$2.52M	$2.32M	$3.09M	$4.39M	$5.78M	$3.51M	$6.34M
High Forecast	$358.19M	$296.93M	$192.80M	$187.12M	$115.46M	$101.66M	$116.73M	$69.56M	$72.77M	$36.59M	$22.23M	$17.67M	$87.16M	$15.85M	$76.72M	$59.01M	$15.17M	$4.57M	$3.14M	$7.08M	$14.75M	$21.76M	$2.53M	$2.52M	$2.32M	$3.09M	$4.39M	$5.78M	$3.51M	$6.34M
Low Forecast	$107.88M	$89.43M	$58.07M	$56.36M	$34.78M	$30.62M	$35.16M	$39.34M	$31.07M	$36.59M	$22.23M	$17.67M	$8.85M	$15.85M	$23.11M	$17.77M	$4.57M	$4.57M	$3.14M	$7.08M	$14.75M	$21.76M	$2.53M	$2.52M	$2.32M	$3.09M	$4.39M	$5.78M	$3.51M	$6.34M
# Analysts	2	2	2	2	1	1	1	4	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.90%	-	0.21%	2.10%	16.41%	2.93%	8.64%	0.74%	0.39%	0.11%	0.79%	0.85%	0.96%	0.75%	0.53%	0.46%	0.85%	0.52%

Arcturus Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $17.67M, with a low forecast of $17.67M, and a high forecast of $17.67M. ARCT's average Quarter revenue forecast represents a -48.02% decrease compared to the company's last Quarter revenue of $33.99M (Dec 23).

Arcturus Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-15.14M	-	$-55.37M	$-18.87M	$125.29M	$-35.95M	$-21.72M	$-50.38M	$-38.35M	$-53.08M	$-53.58M	$-55.49M	$-30.64M	$-20.59M	$-9.86M	$-9.34M	$-11.14M	$-6.86M
Avg Forecast	$-142.17M	$-117.85M	$-76.52M	$-74.27M	$-45.83M	$-40.35M	$-46.33M	$-32.72M	$-28.35M	$-22.59M	$-13.73M	$-52.47M	$-23.37M	$-9.79M	$-30.45M	$-41.48M	$-55.57M	$-2.69M	$-1.85M	$-32.79M	$-8.71M	$-12.84M	$-1.49M	$-30.91M	$-1.37M	$-1.83M	$-2.59M	$-8.42M	$-2.07M	$-3.74M
High Forecast	$-66.60M	$-55.21M	$-35.85M	$-34.79M	$-21.47M	$-18.90M	$-21.70M	$-24.28M	$-19.18M	$-22.59M	$-13.73M	$-41.97M	$-5.47M	$-9.79M	$-14.26M	$-33.18M	$-44.45M	$-2.69M	$-1.85M	$-26.23M	$-8.71M	$-12.84M	$-1.49M	$-24.73M	$-1.37M	$-1.83M	$-2.59M	$-6.74M	$-2.07M	$-3.74M
Low Forecast	$-221.12M	$-183.30M	$-119.02M	$-115.52M	$-71.28M	$-62.76M	$-72.06M	$-42.94M	$-44.92M	$-22.59M	$-13.73M	$-62.96M	$-53.80M	$-9.79M	$-47.36M	$-49.77M	$-66.68M	$-2.69M	$-1.85M	$-39.34M	$-8.71M	$-12.84M	$-1.49M	$-37.09M	$-1.37M	$-1.83M	$-2.59M	$-10.11M	$-2.07M	$-3.74M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.65%	-	1.82%	0.45%	-2.25%	13.34%	11.73%	1.54%	4.41%	4.13%	35.85%	1.80%	22.34%	11.28%	3.80%	1.11%	5.38%	1.83%

3 analysts predict ARCT's average Quarter EBITDA for Mar 23 to be $-41.48M, with a high of $-33.18M and a low of $-49.77M. This is -133.10% lower than Arcturus Therapeutics's previous annual EBITDA (Dec 22) of $125.29M.

Arcturus Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-8.57M	-	$-52.55M	$50.75M	$117.35M	$-34.50M	$-21.04M	$-51.96M	$-38.66M	$-54.08M	$-54.58M	$-56.35M	$-31.10M	$-21.00M	$-10.26M	$-9.78M	$-10.99M	$-7.43M
Avg Forecast	$55.67M	$28.08M	$10.62M	$17.00M	$-5.28M	$-14.34M	$721.66K	$-16.69M	$-15.29M	$-32.91M	$-40.55M	$-53.45M	$-26.85M	$-45.78M	$-6.62M	$-42.25M	$-56.02M	$-48.79M	$-50.23M	$-33.40M	$-44.01M	$-40.35M	$-59.80M	$-31.38M	$-23.46M	$-13.14M	$-14.70M	$-8.82M	$-14.37M	$-9.76M
High Forecast	$95.87M	$48.35M	$18.28M	$29.27M	$-1.63M	$-4.43M	$1.24M	$-5.10M	$20.04M	$-10.17M	$-12.53M	$-42.76M	$-23.51M	$-14.15M	$-2.05M	$-33.80M	$-44.81M	$-48.79M	$-50.23M	$-26.72M	$-44.01M	$-40.35M	$-59.80M	$-25.11M	$-23.46M	$-13.14M	$-14.70M	$-7.05M	$-14.37M	$-9.76M
Low Forecast	$17.20M	$8.68M	$3.28M	$5.25M	$-9.09M	$-24.70M	$222.98K	$-31.99M	$-37.71M	$-56.67M	$-69.82M	$-64.14M	$-30.03M	$-78.83M	$-11.40M	$-50.70M	$-67.22M	$-48.79M	$-50.23M	$-40.08M	$-44.01M	$-40.35M	$-59.80M	$-37.66M	$-23.46M	$-13.14M	$-14.70M	$-10.58M	$-14.37M	$-9.76M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.32%	-	7.94%	-1.20%	-2.09%	0.71%	0.42%	1.56%	0.88%	1.34%	0.91%	1.80%	1.33%	1.60%	0.70%	1.11%	0.76%	0.76%

Arcturus Therapeutics's average Quarter net income forecast for Jun 23 is $-6.62M, with a range of $-11.40M to $-2.05M. ARCT's average Quarter net income forecast represents a -113.05% decrease compared to the company's last Quarter net income of $50.75M (Mar 23).

Arcturus Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$12.51M	-	$13.22M	$13.76M	$11.86M	$12.49M	$10.99M	$10.73M	$10.81M	$10.86M	$10.04M	$9.74M	$9.03M	$5.57M	$4.42M	$4.19M	$1.79M	$3.88M
Avg Forecast	$320.39M	$265.59M	$172.45M	$167.38M	$103.28M	$90.94M	$104.41M	$73.73M	$63.88M	$50.91M	$30.93M	$11.21M	$52.67M	$22.05M	$68.62M	$8.86M	$13.57M	$6.33M	$4.35M	$7.00M	$20.47M	$30.18M	$3.51M	$3.49M	$3.22M	$4.29M	$6.10M	$3.78M	$4.87M	$8.80M
High Forecast	$498.31M	$413.08M	$268.22M	$260.33M	$160.63M	$141.43M	$162.39M	$96.77M	$101.24M	$50.91M	$30.93M	$13.45M	$121.25M	$22.05M	$106.73M	$10.63M	$21.10M	$6.33M	$4.35M	$8.41M	$20.47M	$30.18M	$3.51M	$3.49M	$3.22M	$4.29M	$6.10M	$4.53M	$4.87M	$8.80M
Low Forecast	$150.09M	$124.42M	$80.79M	$78.41M	$48.38M	$42.60M	$48.91M	$54.73M	$43.22M	$50.90M	$30.93M	$8.97M	$12.32M	$22.05M	$32.15M	$7.09M	$6.35M	$6.33M	$4.35M	$5.60M	$20.47M	$30.18M	$3.51M	$3.49M	$3.22M	$4.29M	$6.10M	$3.02M	$4.87M	$8.80M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.24%	-	0.19%	1.55%	0.87%	1.97%	2.53%	1.53%	0.53%	0.36%	2.86%	2.79%	2.80%	1.30%	0.73%	1.11%	0.37%	0.44%

Arcturus Therapeutics's average Quarter SG&A projection for Mar 24 is $11.21M, based on 3 Wall Street analysts, with a range of $8.97M to $13.45M. The forecast indicates a -10.38% fall compared to ARCT last annual SG&A of $12.51M (Dec 23).

Arcturus Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	7	3	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.32	-	$-1.98	$1.91	$4.43	$-1.30	$-0.80	$-1.97	$-1.47	$-2.05	$-2.07	$-2.15	$-1.19	$-0.92	$-0.55	$-0.67	$-0.76	$-0.56
Avg Forecast	$2.06	$1.04	$0.39	$0.63	$-0.20	$-0.53	$0.03	$-0.62	$-0.56	$-1.22	$-1.50	$-1.23	$-0.99	$-1.69	$-0.24	$0.06	$-1.72	$-1.81	$-1.86	$-1.44	$-1.63	$-1.50	$-2.22	$-1.25	$-0.87	$-0.49	$-0.55	$-0.59	$-0.53	$-0.36
High Forecast	$3.54	$1.79	$0.68	$1.08	$-0.06	$-0.16	$0.05	$-0.19	$0.74	$-0.38	$-0.46	$-0.38	$-0.87	$-0.52	$-0.08	$0.10	$-0.53	$-1.81	$-1.86	$-1.44	$-1.63	$-1.50	$-2.22	$-1.25	$-0.87	$-0.49	$-0.55	$-0.59	$-0.53	$-0.36
Low Forecast	$0.64	$0.32	$0.12	$0.19	$-0.34	$-0.91	$0.01	$-1.18	$-1.39	$-2.09	$-2.58	$-2.12	$-1.11	$-2.91	$-0.42	$0.02	$-2.96	$-1.81	$-1.86	$-1.44	$-1.63	$-1.50	$-2.22	$-1.25	$-0.87	$-0.49	$-0.55	$-0.59	$-0.53	$-0.36
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.32%	-	8.09%	32.00%	-2.58%	0.72%	0.43%	1.37%	0.90%	1.37%	0.93%	1.72%	1.36%	1.89%	1.01%	1.14%	1.43%	1.55%

According to 3 Wall Street analysts, Arcturus Therapeutics's projected average Quarter EPS for Jun 23 is $-0.24, with a low estimate of $-0.42 and a high estimate of $-0.08. This represents a -112.81% decrease compared to ARCT previous annual EPS of $1.91 (Mar 23).

Arcturus Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
FDMT	4D Molecular Therapeutics	$6.32	$38.33	506.49%	Buy
BMEA	Biomea Fusion	$4.64	$23.33	402.80%	Buy
GOSS	Gossamer Bio	$0.87	$3.75	331.03%	Buy
NTLA	Intellia Therapeutics	$13.13	$53.00	303.66%	Buy
FATE	Fate Therapeutics	$1.88	$5.00	165.96%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
BEAM	Beam Therapeutics	$28.58	$55.00	92.44%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
CRSP	CRISPR Therapeutics	$44.63	$77.50	73.65%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
CRBU	Caribou Biosciences	$1.94	$3.00	54.64%	Buy
ETNB	89bio	$7.98	$12.00	50.38%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy
ARCT	Arcturus Therapeutics	$15.73	$9.58	-39.10%	Buy

ARCT Forecast FAQ

Is Arcturus Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, Arcturus Therapeutics (ARCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of ARCT's total ratings.

What is ARCT's price target?

Arcturus Therapeutics (ARCT) average price target is $9.58 with a range of $8.58 to $10.58, implying a -38.11% from its last price of $15.48. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arcturus Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ARCT stock, the company can go down by -38.11% (from the last price of $15.48 to the average price target of $9.58), down by -31.65% based on the highest stock price target, and down by -44.57% based on the lowest stock price target.

Can Arcturus Therapeutics stock reach $20?

ARCT's average twelve months analyst stock price target of $9.58 does not support the claim that Arcturus Therapeutics can reach $20 in the near future.

What are Arcturus Therapeutics's analysts' financial forecasts?

Arcturus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $267.65M (high $403.42M, low $139.89M), average EBITDA is $-165M (high $-86.358M, low $-249M), average net income is $-35.587M (high $-9.919M, low $-65.547M), average SG&A $372.35M (high $561.23M, low $194.62M), and average EPS is $-1.315 (high $-0.367, low $-2.422). ARCT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $665.48M (high $1.04B, low $311.74M), average EBITDA is $-411M (high $-192M, low $-639M), average net income is $111.37M (high $191.77M, low $34.41M), average SG&A $925.82M (high $1.44B, low $433.7M), and average EPS is $4.12 (high $7.09, low $1.27).

Did the ARCT's actual financial results beat the analysts' financial forecasts?

Based on Arcturus Therapeutics's last annual report (Dec 2023), the company's revenue was $169.93M, beating the average analysts forecast of $140.98M by 20.54%. Apple's EBITDA was $-75.071M, missing the average prediction of $-105M by -28.56%. The company's net income was $-26.591M, missing the average estimation of $-122M by -78.12%. Apple's SG&A was $52.87M, missing the average forecast of $152.21M by -65.27%. Lastly, the company's EPS was $-1, missing the average prediction of $-2.869 by -65.14%. In terms of the last quarterly report (Dec 2023), Arcturus Therapeutics's revenue was $33.99M, missing the average analysts' forecast of $37.86M by -10.23%. The company's EBITDA was $-15.138M, missing the average prediction of $-23.374M by -35.23%. Arcturus Therapeutics's net income was $-8.573M, missing the average estimation of $-26.848M by -68.07%. The company's SG&A was $12.51M, missing the average forecast of $52.67M by -76.26%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-0.992 by -67.75%